stockrow
Friday 6 November 2026
Export IMCC’s income statement to Excel — free account
IM Cannabis Corp.
IMCC Healthcare Drug Manufacturers Specialty & Generic
IM Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 0.66% from fiscal 2024.
- Revenue
- −40.3%
- EPS
- −385.7%
- Free cash flow
- −266.8%
- Total debt
- −64.7%
Quarter to June 2026, against a year earlier
0.61
0.02
+3.39%
Follow IMCC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 7 | 12 | 43 | 42 | 36 | 39 | 39 | 33 | +33.3% | 62 | — | — | +59.2% | |
| Gross margin, % | 0.00 | — | — | (22.71) | 55.44 | 21.88 | 20.78 | 20.17 | 15.64 | 17.70 | 12.62 | +17.7 pt | ||||||
| EBT | 0 | 0 | 0 | (6) | (21) | (14) | (20) | (7) | (9) | (8) | (13) | +84.4% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | (80.77) | (179.18) | (33.17) | (47.96) | (19.38) | (23.68) | (21.30) | (40.24) | (21.3) pt | ||||||
| Net income | 0 | 0 | 0 | (6) | (21) | (15) | (147) | (8) | (9) | (8) | (13) | +84.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 2.18 | 554.29 | 1,345.53 | 1,047.48 | 507.78 | 504.24 | 277.42 | 107.24 | n/m | |||||
| Earnings | (0.01) | (0.01) | (0.35) | (1.75) | (990.79) | (450.36) | (3,644.32) | (99.08) | (98.80) | (57.36) | (76.98) | +150.4% | ||||||
| Cash flow | (0.01) | 0.00 | (0.26) | (1.43) | (276.24) | (851.72) | (243.68) | (84.02) | (10.05) | 23.90 | (1.54) | n/m | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | (94.53) | (113.86) | (26.07) | (6.04) | (0.56) | (0.07) | (0.03) | n/m | ||||||
| Free cash flow | (0.01) | 0.00 | (0.26) | (1.43) | (370.77) | (965.58) | (269.74) | (90.06) | (10.61) | 23.84 | (1.58) | n/m | ||||||
| Book value | 0.00 | 35.24 | 0.00 | 5.93 | 439.88 | 5,078.43 | 458.76 | 142.54 | 29.36 | (18.32) | (13.17) | n/m | ||||||
| Shares, m | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (27.6%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 0.00 | 25.27 | 4.47 | 0.19 | 0.12 | 0.14 | 0.15 | 0.01 | 4.3 | ||||||
| P/B | — | — | — | 0.79 | 31.92 | 1.18 | 0.43 | 0.43 | 2.38 | 0.00 | 0.00 | 5.3 | ||||||
| EV/Sales | — | — | — | 0.00 | 24.77 | 4.69 | 0.33 | 0.31 | 0.17 | 0.12 | 0.00 | 4.3 | ||||||
| EV/FCF | — | — | — | 0.00 | (26.12) | (6.54) | (1.27) | (1.75) | (7.92) | 1.36 | 0.26 | (6.0) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | — | 0 | (5) | (6) | (27) | (10) | (6) | (1) | 3 | 0 | n/m | |||||
| Capex | — | — | — | (1) | (2) | (4) | (1) | 0 | 0 | 0 | 0 | (55.5%) | ||||||
| Free cash flow | 0 | — | 0 | (5) | (8) | (31) | (11) | (6) | (1) | 3 | 0 | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 0 | 0 | 17 | 16 | 26 | (1) | (6) | (8) | (8) | (9) | +43.7% | |||||
| Net debt | 0 | 0 | 0 | (10) | (6) | 10 | 6 | (1) | 1 | (1) | (1) | n/m | ||||||
| Shareholders’ equity | — | 9 | — | 19 | 9 | 164 | 18 | 10 | 2 | (3) | (4) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (14,615.39) | (11,376.00) | (2,658.95) | (47.19) | (82.05) | (11.00) | (105.29) | (16.99) | (23.86) | (31.57) | (54.20) | +14,583.8 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (109.50) | (11.05) | (61.22) | (65.10) | (137.46) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (0.39) | (0.14) | (1.05) | (41.07) | (150.96) | (16.39) | (159.81) | (49.46) | (124.14) | 5,561.96 | 2,280.06 | +5,562.4 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 153 | 95 | 55 | 44 | — | (34.0%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.27 | 0.38 | 0.72 | 0.89 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026
IM Cannabis Corp. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| APUS Apimeds Pharmaceuticals US, Inc. | $4.1M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| RDHL Redhill Biopharma Ltd. | $3.8M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| PRFX PainReform Ltd. | $2.3M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AKAN Akanda Corp. | $2.2M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| SBFM Sunshine Biopharma, Inc. | $2.1M | — (loss-making) | — (loss-making) | −1.56% (below 0%: shrinking) | n/m | +49.38% (above 0%: growing) | 26.20% | (17.41%) | Compare |
| SXTC China SXT Pharmaceuticals, Inc. | $2.0M | — (loss-making) | — (loss-making) | −16.76% (below 0%: shrinking) | +92.67% (above 0%: growing) | −107.59% (below 0%: shrinking) | 44.09% | 0.00% | Compare |
| PTPI Petros Pharmaceuticals, Inc. | $1.0M | — (loss-making) | — (loss-making) | +299.12% (above 0%: growing) | n/m | +71.27% (above 0%: growing) | 359.80% | 0.00% | Compare |
| IMCC IM Cannabis Corp. | $980.0K | — (loss-making) | — (loss-making) | −40.28% (below 0%: shrinking) | n/m | −266.81% (below 0%: shrinking) | 19.83% | (27.54%) | |
| Median of peers | $2.3M | — | — | −1.56% | — | −9.28% | 26.20% | 0.00% |